{"id":"https://openalex.org/W3099248962","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0394","title":"394 Interleukin-8\u2013neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti\u2013PD-(L)1\u2013experienced patients with advanced cancer: initial phase 1 results","display_name":"394 Interleukin-8\u2013neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti\u2013PD-(L)1\u2013experienced patients with advanced cancer: initial phase 1 results","publication_year":2020,"publication_date":"2020-11-01","ids":{"openalex":"https://openalex.org/W3099248962","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0394","mag":"3099248962"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0394","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0394","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0394","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0394","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030169825","display_name":"Diwakar Davar","orcid":"https://orcid.org/0000-0002-7846-8055","observed_orcids":["https://orcid.org/0000-0002-7846-8055"]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diwakar Davar","raw_affiliation_strings":["University of Pittsburgh Medical Center, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Medical Center, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021465650","display_name":"Matteo Simonelli","orcid":"https://orcid.org/0000-0002-5264-1251","observed_orcids":["https://orcid.org/0000-0002-5264-1251"]},"institutions":[{"id":"https://openalex.org/I1339471597","display_name":"Humanitas University","ror":"https://ror.org/020dggs04","country_code":"IT","type":"education","lineage":["https://openalex.org/I1339471597"]},{"id":"https://openalex.org/I4210163047","display_name":"IRCCS Humanitas Research Hospital","ror":"https://ror.org/05d538656","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210163047"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Matteo Simonelli","raw_affiliation_strings":["Humanitas University; Humanitas Cancer Center \u2013 Humanitas Research Hospital, Milan, Italy","Humanitas Cancer Center \u2013 Humanitas Research Hospital, Milan, Italy","Humanitas University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Humanitas University; Humanitas Cancer Center \u2013 Humanitas Research Hospital, Milan, Italy","institution_ids":["https://openalex.org/I1339471597"]},{"raw_affiliation_string":"Humanitas Cancer Center \u2013 Humanitas Research Hospital, Milan, Italy","institution_ids":["https://openalex.org/I4210163047"]},{"raw_affiliation_string":"Humanitas University","institution_ids":["https://openalex.org/I1339471597"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102845964","display_name":"Martin E Gutierrez","orcid":"https://orcid.org/0000-0002-3642-2315","observed_orcids":["https://orcid.org/0000-0002-3642-2315"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Gutierrez","raw_affiliation_strings":["Hackensack University Medical Center, Hackensack, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hackensack University Medical Center, Hackensack, NJ, USA","institution_ids":["https://openalex.org/I1324520350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053069942","display_name":"Emiliano Calvo","orcid":"https://orcid.org/0000-0003-4921-829X","observed_orcids":["https://orcid.org/0000-0003-4921-829X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emiliano Calvo","raw_affiliation_strings":["START Madrid-CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START Madrid-CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Madrid, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035594574","display_name":"Jason M. Melear","orcid":"https://orcid.org/0009-0008-7943-8908","observed_orcids":["https://orcid.org/0009-0008-7943-8908"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Melear","raw_affiliation_strings":["Texas Oncology, US Oncology Research, Austin, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology, US Oncology Research, Austin, TX, USA","institution_ids":["https://openalex.org/I2800124591"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026538331","display_name":"Sarina Anne Piha-Paul","orcid":"https://orcid.org/0000-0001-9455-1660","observed_orcids":["https://orcid.org/0000-0001-9455-1660"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarina Piha-Paul","raw_affiliation_strings":["The University of Texas, MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas, MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015961133","display_name":"Donald Richards","orcid":"https://orcid.org/0000-0002-2254-4514","observed_orcids":["https://orcid.org/0000-0002-2254-4514","https://orcid.org/0009-0005-8381-6033"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donald Richards","raw_affiliation_strings":["Texas Oncology, US Oncology Research, Austin, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology, US Oncology Research, Austin, TX, USA","institution_ids":["https://openalex.org/I2800124591"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000060751","display_name":"Matthew C. Dallos","orcid":"https://orcid.org/0000-0002-5412-3490","observed_orcids":["https://orcid.org/0000-0002-5412-3490"]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew Dallos","raw_affiliation_strings":["Columbia University Medical Center, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University Medical Center, New York, NY, USA","institution_ids":["https://openalex.org/I2799503643"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081102636","display_name":"Janaki Parameswaran","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janaki Parameswaran","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009693118","display_name":"Vinit Kumar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vinit Kumar","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078545719","display_name":"Xiaochen Zhao","orcid":"https://orcid.org/0000-0002-6603-257X","observed_orcids":["https://orcid.org/0000-0002-6603-257X"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaochen Zhao","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024778802","display_name":"Santanu Dutta","orcid":"https://orcid.org/0000-0003-3900-6349","observed_orcids":["https://orcid.org/0000-0003-3900-6349"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Santanu Dutta","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5029243551","display_name":"Ignacio Melero","orcid":"https://orcid.org/0000-0002-1360-348X","observed_orcids":["https://orcid.org/0000-0002-1360-348X"]},"institutions":[{"id":"https://openalex.org/I88155538","display_name":"Universidad de Navarra","ror":"https://ror.org/02rxc7m23","country_code":"ES","type":"education","lineage":["https://openalex.org/I88155538"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Ignacio Melero","raw_affiliation_strings":["Universidad de Navarra, Pamplona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universidad de Navarra, Pamplona, Spain","institution_ids":["https://openalex.org/I88155538"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A239.2","last_page":"A240"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11532","display_name":"Chemokine receptors and signaling","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interleukin-8","display_name":"interleukin-8","score":0.9559999704360962},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9380000233650208},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.671999990940094},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.8140000104904175},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.44699999690055847},{"id":"https://openalex.org/keywords/biomarker-enrichment","display_name":"biomarker enrichment","score":0.45500001311302185},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.49799999594688416},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.47699999809265137},{"id":"https://openalex.org/keywords/pd-l1-negative-tumors","display_name":"PD-L1-negative tumors","score":0.4269999861717224},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.4690000116825104},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9539999961853027},{"id":"https://openalex.org/keywords/squamous-cell-carcinoma","display_name":"squamous cell carcinoma","score":0.6489999890327454},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.9789999723434448},{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.828000009059906},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.5379999876022339},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.722000002861023},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.6909999847412109},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8519999980926514}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.885690450668335},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.818615198135376},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.6144489049911499},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5567083954811096},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5548372268676758},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5053618550300598},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.49327224493026733},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4846785366535187},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.460559219121933},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43418434262275696},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4317360520362854},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3921979069709778},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3689761757850647},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3402002453804016},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22184190154075623}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2020-sitc2020.0394","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0394","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0394","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:166aa176ac0146108e01f9deabb0d781","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/166aa176ac0146108e01f9deabb0d781","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0394","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0394","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0394","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4311139958","https://openalex.org/W2892330807","https://openalex.org/W4282919931","https://openalex.org/W2890767638","https://openalex.org/W2972293235","https://openalex.org/W3103132093","https://openalex.org/W3167422454","https://openalex.org/W4308383481","https://openalex.org/W4307065670","https://openalex.org/W2890326072"],"abstract_inverted_index":{"Background":[0],"Interleukin":[1],"8":[2],"(IL-8)":[3,543],"is":[4,27,461],"a":[5,28,50,85,345,362,440],"C-X-C":[6],"chemokine":[7],"that":[8],"exerts":[9],"protumorigenic":[10],"effects":[11],"in":[12,32,42,71,89,254,286,289,298,312,366,383,443,495,540,552],"the":[13,99,331,408,420],"tumor":[14,294,314,444],"microenvironment,":[15],"including":[16,316],"recruiting":[17],"immunosuppressive":[18],"PMN-MDSCs":[19],"and":[20,37,59,64,126,161,196,243,278,352,467,517,546,554],"promoting":[21],"angiogenesis.1\u20133":[22],"Elevated":[23,458],"serum":[24,459,541],"IL-8":[25,58,295,519],"(sIL-8)":[26],"negative":[29],"prognostic":[30],"indicator":[31],"patients":[33,43,72,90,114,177,191,256,300,320,333,496],"with":[34,45,73,91,115,208,282,293,321,338,349,373,463,497,521],"solid":[35,118,501],"tumors":[36,119],"may":[38],"have":[39],"predictive":[40],"value":[41],"treated":[44,337],"immunotherapies.2":[46],"4":[47,329],"5":[48,317,332],"BMS-986253,":[49],"fully":[51],"human-sequence":[52],"IgG1\u03ba":[53],"anti\u2013IL-8":[54,492],"monoclonal":[55,493],"antibody,":[56,494],"binds":[57],"prevents":[60],"signaling":[61],"through":[62],"CXCR1/CXCR2":[63],"has":[65],"been":[66],"shown":[67],"to":[68,407,549],"be":[69,306],"safe":[70],"advanced":[74,92,116,374,385],"cancers.3":[75],"We":[76],"present":[77],"initial":[78],"results":[79],"of":[80,101,172,190,222,318,330,364,381,471,488,525],"BMS-986253":[81,134,186,202,259,267,273,284,341,382],"+":[82,152,187,203,263,271,342],"NIVO":[83,153,204,343],"from":[84],"phase":[86],"1/2a":[87],"trial":[88,487],"cancers":[93],"who":[94,323],"had":[95,103,324],"detectable":[96,127],"sIL-8":[97,128,291,354],"levels,":[98,292],"majority":[100],"whom":[102],"progressed":[104,325],"on/after":[105,326],"prior":[106,193,199,327],"anti\u2013PD-(L)1":[107,194],"(NCT03400332).":[108],"Methods":[109],"During":[110],"safety":[111,347],"evaluation/dose":[112],"exploration,":[113],"metastatic":[117,498],"(melanoma,":[120],"NSCLC,":[121],"SCCHN,":[122],"RCC,":[123],"or":[124,139,144,147,499],"UCC)":[125],"(>10":[129],"pg/mL":[130],"at":[131,395],"screening)":[132],"received":[133,185,192,198],"600":[135],"(n=16),":[136],"1200":[137,145,268],"(n=15),":[138],"2400":[140,148,260],"mg":[141,149,155,261,269],"(n=18)":[142],"Q4W,":[143],"(n=12)":[146],"(n=59)":[150],"Q2W,":[151],"480":[154],"intravenously":[156],"Q4W.":[157],"Safety,":[158],"pharmacokinetics,":[159],"pharmacodynamics,":[160],"preliminary":[162],"antitumor":[163,357],"activity":[164,358],"were":[165,215,229,252,310,334],"evaluated":[166],"(investigator-assessed,":[167],"RECIST":[168],"v1.1).":[169],"Results":[170],"As":[171],"March":[173],"20,":[174],"2020,":[175],"120":[176],"(median":[178],"age,":[179],"63":[180],"years":[181],"[range,":[182],"35\u201387":[183],"years])":[184],"NIVO;":[188,264],"97%":[189],"therapy,":[195],"25%":[197],"anti\u2013CTLA-4":[200],"therapy.":[201],"was":[205,279,359,417],"well":[206],"tolerated":[207],"no":[209],"dose-limiting":[210],"toxicities":[211],"observed.":[212],"Most":[213],"TRAEs":[214,224,251],"grade":[216,227],"1\u20132.":[217],"The":[218,388,437],"most":[219,299],"common":[220],"(\u22655%":[221],"patients)":[223],"(any":[225],"grade;":[226],"3\u20134)":[228],"fatigue":[230],"(9%;":[231],"1%),":[232],"nausea":[233],"(7%;":[234],"0%),":[235,239,242],"rash/rash":[236],"maculopapular":[237],"(6%;":[238],"pruritus":[240],"(5%;":[241,246],"decreased":[244],"appetite":[245],"0%).":[247],"Grade":[248],"3\u20134":[249],"serious":[250],"reported":[253],"2":[255],"(infusion-related":[257],"reaction,":[258],"Q2W":[262],"AST/ALT":[265],"increased,":[266],"Q4W":[270],"NIVO).":[272],"exposure":[274],"increased":[275],"dose":[276],"proportionally":[277],"not":[280],"altered":[281],"NIVO.":[283],"resulted":[285],"dose-dependent":[287],"reductions":[288],"free":[290],"suppression":[296],"detected":[297],"evaluated;":[301],"additional":[302],"pharmacodynamic":[303],"endpoints":[304],"will":[305],"presented.":[307],"Partial":[308],"responses":[309],"observed":[311,360],"multiple":[313],"types,":[315],"28":[319],"melanoma":[322,553],"anti\u2013PD-(L)1;":[328],"also":[335],"previously":[336],"anti\u2013CTLA-4.":[339],"Conclusions":[340],"demonstrated":[344],"tolerable":[346],"profile":[348],"dose-proportional":[350],"pharmacokinetics":[351],"robust":[353],"suppression.":[355],"Preliminary":[356],"across":[361],"range":[363],"doses/regimens":[365],"this":[367],"biomarker-enriched,":[368],"anti\u2013PD-(L)1\u2013experienced,":[369],"heterogeneous":[370],"patient":[371],"population":[372],"cancers.":[375],"These":[376],"findings":[377],"support":[378],"further":[379],"evaluation":[380],"select":[384],"tumors.":[386,502],"Acknowledgements":[387],"authors":[389],"acknowledge":[390],"Dr":[391],"Charles":[392],"Drake":[393],"while":[394],"Columbia":[396],"University":[397],"Medical":[398],"Center,":[399],"New":[400],"York,":[401],"NY,":[402],"USA,":[403],"for":[404],"his":[405],"contributions":[406],"study.":[409],"Trial":[410],"Registration":[411],"NCT03400332":[412],"Ethics":[413],"Approval":[414],"This":[415],"study":[416],"approved":[418],"by":[419],"WCG":[421],"Independent":[422],"Review":[423],"Board,":[424],"approval":[425],"number":[426],"20172711.":[427],"References":[428],"David":[429],"JM,":[430,482],"Dominguez":[431],"C,":[432],"Hamilton":[433],"DH,":[434],"et":[435,456,483,513,537],"al.":[436,457,484,514,538],"IL-8/IL-8R":[438],"axis:":[439],"double":[441],"agent":[442],"immune":[445],"resistance.":[446],"Vaccines":[447],"(Basel)":[448],"2016;4:22.":[449],"Schalper":[450,535],"KA,":[451,536],"Carleton":[452],"M,":[453,455,478],"Zhou":[454],"interleukin-8":[460,542],"associated":[462],"enhanced":[464],"intratumor":[465],"neutrophils":[466],"reduced":[468,522],"clinical":[469,523],"benefit":[470,524],"immune-checkpoint":[472],"inhibitors.":[473],"Nat":[474,528],"Med.":[475],"2020;26:688\u2013692.":[476],"Bilusic":[477],"Heery":[479],"CR,":[480],"Collin":[481],"Phase":[485],"I":[486],"HuMax-IL-8":[489],"(BMS-986253),":[490],"an":[491],"unresectable":[500],"J":[503],"Immunother":[504],"Cancer":[505],"2019;7:240.":[506],"Yuen":[507],"KC,":[508],"Liu":[509],"L-F,":[510],"Gupta":[511],"V,":[512],"High":[515],"systemic":[516],"tumor-associated":[518],"correlates":[520],"PD-L1":[526],"blockade.":[527],"Med":[529],"2020;26:683\u2013698.":[530],"Sanmamed":[531],"MF,":[532],"Perez-Gracia":[533],"JL,":[534],"Changes":[539],"levels":[544],"reflect":[545],"predict":[547],"response":[548],"anti\u2013PD-1":[550],"treatment":[551],"non-small-cell":[555],"lung":[556],"cancer":[557],"patients.":[558],"Ann":[559],"Oncol":[560],"2017;28:1988\u20131995.":[561]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-23T00:00:00"}